Recent studies show that amino bisphosphonates, such as alendronate (ALN), inhibit angiogenesis. Additionally, polymer-drug conjugates have been shown to increase the half-life of low molecular weight drugs, water solubility, and tumor accumulation.
The proposed technology is a combined targeted therapy made by conjugating angiogenesis inhibitors ALN and TNP-470 to a copolymer backbone. In vitro studies provide evidence that this copolymer-drug conjugate targets both tumor epithelial and endothelial compartments. These results indicate that the proposed technology represents a promising therapy for osteosarcomas and bone metastases.